Immucell Corp

ICCCNASDAQUSD
8.44 USD
0.09 (1.08%)AT CLOSE (11:59 AM EDT)
8.43
0.01 (0.06%)
POST MARKET (AS OF 04:15 PM EDT)
Post Market
AS OF 04:15 PM EDT
8.43
0.01 (0.06%)
🔴Market: CLOSED
Open?$8.26
High?$8.50
Low?$8.26
Prev. Close?$8.35
Volume?16.3K
Avg. Volume?23.3K
VWAP?$8.44
Rel. Volume?0.70x
Bid / Ask
Bid?$8.07 × 200
Ask?$8.50 × 200
Spread?$0.43
Midpoint?$8.29
Valuation & Ratios
Market Cap?75.5M
Shares Out?9.0M
Float?6.5M
Float %?71.9%
P/E Ratio?N/A
P/B Ratio?2.79
EPS?-$0.11
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?4.26Strong
Quick Ratio?1.93Adequate
Cash Ratio?0.96Adequate
Debt/Equity?0.34Low
ValuationATTRACTIVELY VALUED
Score
80/100
P/E?
N/A
P/B?
2.79CHEAP
P/S?
2.73CHEAP
P/FCF?
61.7PRICEY
EV/EBITDA?
18.5FAIR
EV/Sales?
2.92CHEAP
Returns & Efficiency
ROE?
-3.8%WEAK
ROA?
-2.5%WEAK
Cash Flow & Enterprise
FCF?$1.2M
Enterprise Value?$80.8M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Employees
73
Market Cap
75.5M
Industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Listed
1987-07-08
Address
56 EVERGREEN DR
PORTLAND, ME 04103
Phone: (207) 878-2770